ClinicalTrials.gg

Program

polyethylene glycol 3350

Also written as “NER1006”, “polyethyleneglycol3350” and “HalfLytely”.

Its studies are mostly in Constipation · Colonic Neoplasms · Opioid-Induced Constipation · Colorectal Neoplasms · Enterocolitis, Pseudomembranous, led by 4 companies.

Furthest: phase 4, since Sep 7, 200515 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sebela Pharmaceuticals100 open or runningphase 4since Sep 7, 2005Sep 7, 2005none ahead
Bayer30 open or runningphase 4since Oct 9, 2008Oct 9, 2008none ahead
Ascension Health10 open or runningphase 4since Jun 21, 2012Jun 21, 2012none ahead
Taejoon Pharmaceutical10 open or runningphase 3since Apr 21, 2023Apr 21, 2023none ahead

Also a collaborator on its studies: Parexel, Quotient Sciences and Pierrel Research Europe.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 7, 2005First studies: 6 phase 4 studiesNew to Sebela PharmaceuticalsSebela Pharmaceuticals · NCT00153153, NCT00153140, NCT00153127 and 3 more
  2. Sep 9, 20052 phase 3 studies in ColonoscopySebela Pharmaceuticals · NCT00164164, NCT00164151
  3. Apr 27, 2006Phase 4 study in ConstipationSebela Pharmaceuticals · NCT00319670 · 25 enrolled · United States
  4. Dec 20, 2007Phase 4 study in ConstipationSebela Pharmaceuticals · NCT00583609 · 20 enrolled · United States
  5. Oct 9, 2008Bayer’s first study: phase 4 study in ConstipationNew to BayerBayer · NCT00770432 · 203 enrolled
  6. Sep 29, 2010Phase 2 study in ConstipationBayer · NCT01212445 · 154 enrolled · Ireland
  7. Jun 21, 2012Ascension Health’s first study: phase 4 study in Enterocolitis, PseudomembranousNew to Ascension HealthAscension Health · NCT01630096 · 200 enrolled · United States
  8. Nov 12, 2014Phase 3 study in ConstipationBayer · NCT02292459
  9. Apr 21, 2023Taejoon Pharmaceutical’s first study: phase 3 study in Bowel PreparationNew to Taejoon PharmaceuticalTaejoon Pharmaceutical · NCT05870553 · 137 enrolled · Korea, Republic of

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 15 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT05870553Bowel Preparation · Korea, Republic of3CompletedTaejoon PharmaceuticalMay 12, 2023137
NCT02292459Constipation3WithdrawnBayerDec 20150
NCT01630096Enterocolitis, Pseudomembranous · United States4UNKNOWNAscension HealthJun 2014200
NCT01212445Constipation · Ireland2CompletedBayerNov 2011154
NCT00770432Constipation4CompletedBayerJan 2008203
NCT00583609Constipation · United States4CompletedSebela PharmaceuticalsJul 200820
NCT00319670Constipation · United States4CompletedSebela PharmaceuticalsMay 200625
NCT00164177Colonoscopy · United States4CompletedSebela PharmaceuticalsDec 200420
NCT00164164Colonoscopy · United States3CompletedSebela PharmaceuticalsJun 2000200
NCT00164151Colonoscopy · United States3CompletedSebela PharmaceuticalsMay 200260
NCT00164125Constipation · United States4CompletedSebela PharmaceuticalsNov 2004300
NCT00153153Constipation · United States4CompletedSebela PharmaceuticalsDec 2004300
NCT00153140Constipation · United States4CompletedSebela PharmaceuticalsOct 2004239
NCT00153127Constipation · United States4CompletedSebela PharmaceuticalsSep 2004100
NCT00153114Constipation · United States4CompletedSebela PharmaceuticalsSep 2004100

How it is read

Names in the registry

  • “NER1006”, 9 entries
  • “polyethyleneglycol3350”, 5 entries
  • “HalfLytely”, 3 entries
  • “PEG 3350 plus electrolytes”, 2 entries
  • “PLENVU®”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.